लोड हो रहा है...
Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
INTRODUCTION: There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson’s disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamic...
में बचाया:
| में प्रकाशित: | Neurol Ther |
|---|---|
| मुख्य लेखकों: | , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Springer Healthcare
2018
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6283789/ https://ncbi.nlm.nih.gov/pubmed/30361858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-018-0114-z |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|